Press Releases
AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021
MASON, Ohio --(BUSINESS WIRE)--Aug. 31, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 19 th Annual...
AtriCure Reports Second Quarter 2021 Financial Results
August 04, 2021
MASON, Ohio --(BUSINESS WIRE)--Aug. 4, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by...
AtriCure to Participate at the Canaccord 41st Annual Growth Conference
July 30, 2021
MASON, Ohio --(BUSINESS WIRE)--Jul. 30, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41 st Annual Growth...
AtriCure to Announce Second Quarter 2021 Financial Results
July 07, 2021
MASON, Ohio --(BUSINESS WIRE)--Jul. 7, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021 ....
AtriCure Names Two New Members to the Board of Directors
June 15, 2021
MASON, Ohio --(BUSINESS WIRE)--Jun. 15, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms....
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
April 29, 2021
FDA approval results in the only label of its kind for more than 3 million patients in the United States , significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for...
AtriCure Reports First Quarter 2021 Financial Results
April 27, 2021
MASON, Ohio --(BUSINESS WIRE)--Apr. 27, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results. “Our growth in the first quarter is a testament of our...
AtriCure Names B. Kristine Johnson Board Chair
April 08, 2021
MASON, Ohio --(BUSINESS WIRE)--Apr. 8, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair....
AtriCure to Announce First Quarter 2021 Financial Results
April 06, 2021
MASON, Ohio --(BUSINESS WIRE)--Apr. 6, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021 ....
AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference
March 02, 2021
MASON, Ohio --(BUSINESS WIRE)--Mar. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual...